Home

News
World’s first monoclonal antibody against vasoinhibin developed in Nuremberg (April 2026)Monoclonal antibodies against vasoinhibin (also known as 16K PRL) capable for ELISA are commercially available from Davids Biotechnologie GmbH (Regensburg, Germany).Now accepting submissions — Communications in Prolactin Research, the first journal dedicated to prolactinPatent filed: vasoinhibin-binding monoclonal antibody (WO/2025/098661)Call for submissions: Macroprolactinaemia — Communications in Prolactin Research
Portrait of Jakob Triebel
Assoc. Prof. Jakob Triebel, MD

Physician-scientist · Laboratory medicine · Prolactin and vasoinhibin research

Institute for Laboratory Medicine and Infectious Diseases
General Hospital Nuremberg & Paracelsus Medical University Nuremberg

Editor-in-Chief · Communications in Prolactin Research

My research addresses the biology of prolactin and vasoinhibin — a prolactin fragment that regulates the growth and function of blood vessels. The work spans molecular mechanisms, the development of monoclonal antibodies (Vi-Mab), and their translation into laboratory diagnostics and clinical utilization.

Research focus

Prolactin & vasoinhibin

Molecular biology and physiology of the prolactin/vasoinhibin axis with a role in vascular regulation.

Monoclonal antibodies

Development and validation of vasoinhibin-specific antibodies (Vi-Mab).

Translational diagnostics

Turning research tools into assays for laboratory medicine.

Journal

Communications in Prolactin Research

As Editor-in-Chief, I lead Communications in Prolactin Research — the first peer-reviewed journal dedicated entirely to the hormone prolactin. If your work touches prolactin biology or the prolactin/vasoinhibin axis, you are warmly invited to explore the journal and consider submitting your manuscript.

Visit the journal ↗

Recognition & profiles

Expertscape World Expert 2023 - Prolactin